Dr. Lorenzo Gianni - Oncologia Rimini
Dr. Lorenzo Gianni - Oncologia Rimini
Dr. Lorenzo Gianni - Oncologia Rimini
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Complicazioni chirurgiche: non<br />
significativo aumento<br />
The current CDDP recommendation CDDP +<br />
is P<br />
that bevacizumab be discontinued at<br />
least 28 days before BV<br />
surgery. Caution is needed when reconstruction is<br />
being considered; bevacizumab should be nelle discontinued deiscenze at least ferita<br />
6<br />
Tutte 11 (39%) 22 (43%) 0.82<br />
weeks before surgery in this scenario, with – the Tutti possibility i casi of con deferring BV<br />
tissue expander reconstruction. Bevacizumab can be initiated at least<br />
Sieroma 5 (18%) 5 (10%) NS – Nessuno con CDDP<br />
28 days after surgery and then only if the surgical wound is fully<br />
(aspirazioni<br />
healed.<br />
multiple)<br />
Deiscenza<br />
ferita<br />
2 (7%) 8 (16%) NS<br />
Ematoma 2 (7%) 5 (10%) NS<br />
Ascesso 2 (7%) 0 (0%) NS<br />
Perdita<br />
ricostruzione<br />
0/5 (0%) 4/8 (50%) 0.10<br />
• Revisione chirurgica e/o<br />
drenaggio in aspirazione<br />
• Uso expander forse<br />
problematico<br />
Golshan M, et al. SABCS 2009, #43<br />
#SABCS09_GS4_03
Change language